A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

The incidence of HER2 somatic mutations in breast cancer is about 2–4%, mainly occurring in the HR+/HER2- subtype. Preclinical studies suggest that HER2 mutations can lead to constitutive HER2 activation, but effective treatment options for the clinical management of patients with HER2 mutations rem...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jing Ma, Xuelu Li, Qianran Zhang, Ning Li, Siwen Sun, Shanshan Zhao, Zuowei Zhao, Man Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-07-01
Edice:	Translational Oncology
Témata:	HER2 mutation Breast cancer HER2-targeted therapy Everolimus Treatment
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1936523322001036
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!